What did @verydarkblakmanupdate actually say?
The video opens with a woman claiming she developed osteoporosis and osteopenia after one year on Ozempic for weight loss. She says she had "significant bone loss" confirmed at a doctor's visit, and attributes it directly to the drug. The account's host, @verydarkblakmanupdate, then reposted it as a warning to Nigerian viewers, framing semaglutide as broadly dangerous and urging people to just "control your mouth" and go to the gym instead.
The core claim being amplified here is this: one year of Ozempic use caused a young woman to develop measurable, clinically diagnosed bone density loss. That is a specific medical claim with testable evidence behind it. Let's test it.
Does the science back this up?
Partially, yes, but the relationship is more complicated than the video suggests. The honest answer is that rapid, significant weight loss from any cause, including GLP-1 use, can reduce bone mineral density, and the research does flag this as a real concern worth monitoring.
A 2023 study by Bikou et al. in Nutrients reviewed bone metabolism changes in patients on GLP-1 receptor agonists and found that while GLP-1 receptors exist in bone tissue and may have some direct protective effects, the rapid fat and lean mass loss associated with these drugs can reduce bone mineral density, particularly in older adults. A separate 2022 trial (the STEP 1 extension, Wilding et al., Nature Medicine) noted that participants lost lean mass alongside fat mass, which matters for bone loading. The SURMOUNT trials for tirzepatide raised similar flags. Notably, the FDA label for Wegovy does not list osteoporosis as a known adverse event, but clinicians are increasingly watching for it, especially in patients who are already lean or who lose weight rapidly without resistance training.
So the biological plausibility is real. The leap from "plausible" to "Ozempic gave me osteoporosis in one year" is where the evidence gets thinner.
What did they get wrong (or right)?
Credit where it is due: the concern about bone density in people using GLP-1 drugs for weight loss is not made up. Researchers and endocrinologists are actively studying it. The woman in the original clip appears to have received a real diagnosis, and her doctor apparently connected it to her weight loss. That is not nothing.
But several things in the video are either overstated or flat-out wrong.
- Attributing osteoporosis solely to one year of Ozempic ignores other variables. Bone density is influenced by genetics, baseline calcium and vitamin D intake, activity level, prior dieting history, and hormonal status. A diagnosis of osteoporosis at a young age without ruling out those factors is not a controlled experiment.
- The host's commentary that people should just "control your mouth" and diet naturally is medically naive. Obesity is a chronic disease with neurobiological drivers. The American Diabetes Association and Endocrine Society both classify it as such. Willpower framing is not a treatment plan.
- Neither speaker mentions that bone density loss during GLP-1 therapy is specifically associated with not doing resistance training and not supplementing adequately, two modifiable factors. The drug is not the whole story.
- "It's become very normalized, but it's really dangerous" is a generalization that does not reflect the actual risk-benefit profile for people with obesity or type 2 diabetes, where the cardiovascular and metabolic benefits of semaglutide are well-documented (SELECT trial, Lincoff et al., 2023, NEJM).
What should you actually know?
GLP-1 drugs do carry a real, underappreciated risk of lean mass and bone density loss, particularly when used without structured resistance exercise and adequate protein intake. This is not fearmongering. It is an active clinical conversation.
If you are on or considering semaglutide or tirzepatide, here is what the evidence actually supports doing:
- Get a baseline DEXA scan if you are at risk for bone loss (family history, low body weight, hormonal issues, prior fractures).
- Prioritize resistance training. Studies consistently show that preserving muscle during weight loss protects bone density.
- Ensure adequate calcium (1,000-1,200 mg/day for adults) and vitamin D (discuss with your provider).
- Adequate protein intake during GLP-1 therapy is associated with better lean mass retention (Bray et al., 2012, JAMA, and more recent GLP-1-specific analyses).
What you should not do is take one person's TikTok experience as a reason to avoid a drug that has demonstrated cardiovascular mortality reduction in a 17,604-person randomized trial. Individual anecdotes carry real emotional weight, and this woman's distress is genuine. But medical decisions should be made with a prescribing clinician who knows your full history, not based on a reposted viral video.